Intangible Assets

NNOX has limited evidence of durable intangible assets because its value proposition is still centered on a single emerging imaging platform rather than a broad, entrenched clinical standard, unlike larger radiology incumbents with established installed bases and brand trust.

Regulatory and clinical validation can create some protection, but that protection is narrower than peers with long-cleared, widely adopted imaging ecosystems, so it does not yet translate into strong pricing power.

The company’s negative TTM ROIC and ROCE indicate that any proprietary know-how has not yet converted into durable economic returns, which is weaker than profitable medtech peers with proven intangible leverage.

Because the platform remains early in adoption and has not demonstrated sustained margin durability, its intangible advantage is still more aspirational than structurally embedded versus peers.

Switching Costs

Switching costs are low because hospitals can evaluate alternative imaging systems without being locked into a large software, consumables, or workflow stack that would make replacement operationally painful.

Compared with peers that benefit from installed-base service contracts, recurring consumables, or deeply embedded clinical workflows, NNOX appears to have materially weaker retention economics.

The company has not yet shown evidence of high customer lock-in through long-lived utilization, which limits its ability to defend pricing or expand margins over 5–10 years.

Negative profitability and low asset turnover suggest the current customer relationship is not yet strong enough to create the kind of switching friction seen in more mature medtech platforms.

Network Effects

NNOX does not appear to benefit from meaningful network effects because adoption by one hospital does not materially increase the utility of the platform for other customers in the way software or marketplace businesses do.

Clinical reference value can help sales, but that is weaker than true network effects and is less durable than the ecosystem pull seen at larger peer platforms with broad installed bases.

There is no clear evidence that data accumulation or user scale has created a self-reinforcing adoption loop that would improve product value versus peers over time.

As a result, network effects are not currently a material source of moat durability or peer outperformance.

Cost Advantage

NNOX shows no clear cost advantage because its negative ROIC and ROCE indicate that unit economics are not yet superior to peers on a durable basis.

Asset turnover of 0.10 suggests the asset base is not being leveraged efficiently enough to support a structural cost edge versus established imaging competitors.

Without evidence of scale-driven manufacturing, service, or distribution cost leadership, the company cannot yet underprice peers while preserving margins.

Compared with larger medtech rivals that spread fixed costs across broader product portfolios, NNOX remains structurally disadvantaged on cost absorption.

Efficient Scale

Efficient scale is limited because the imaging market is competitive and large enough to support multiple vendors, which reduces the chance that NNOX can profitably dominate a niche without retaliation.

Unlike regulated local utilities or highly concentrated infrastructure markets, the company does not operate in a segment where one provider can naturally earn excess returns from scarcity.

Peer incumbents with broader installed bases and service networks can defend accounts more effectively, which makes it harder for NNOX to convert scale into durable pricing power.

The current financial profile does not show evidence that scale is already creating a self-reinforcing moat, so efficient scale remains weak versus peers.

Overall Score

NNOX currently shows a weak moat versus peers because none of the five structural drivers is yet strong enough to support durable pricing power, retention, or margin resilience over 5–10 years, and the negative TTM ROIC/ROCE reinforce that its platform has not yet translated into lasting economic advantage.